Administration of the Potent PPARα Agonist, Wy-14,643, Reverses Nutritional Fibrosis and Steatohepatitis in Mice

Hepatology

Volumn 39, Issue 5, 2004, Pages 1286-1296

  Ip, Emilia ^a   Farrell, Geoff ^a,e   Hall, Pauline ^b   Robertson, Graham ^c   Leclercq, Isabelle ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c University of Sydney   (Australia)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLINE; COLLAGEN TYPE 1; COLLAGENASE 3; LIPID PEROXIDE; MESSENGER RNA; METHACHOLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRINIXIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULAR CELL ADHESION MOLECULE 1; CELL ADHESION MOLECULE; CELL RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; IMMEDIATE EARLY PROTEIN; PEROXISOME PROLIFERATOR; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG POTENCY; GENE EXPRESSION; HEPATITIS; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER METABOLISM; MACROPHAGE ACTIVATION; MALE; METHIONINE AND CHOLINE DEFICIENT DIET; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STEATOHEPATITIS; STEATOSIS; STELLATE CELL; STIMULUS RESPONSE; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; DRUG EFFECT; DRUG POTENTIATION; FAT INTAKE; FATTY LIVER; GENETICS; LIVER CELL; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ANIMALS; CELL ADHESION MOLECULES; DIETARY FATS; FATTY LIVER; GENE EXPRESSION; HEPATOCYTES; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID PEROXIDES; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; PEROXISOME PROLIFERATORS; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIGLYCERIDES;

EID: 2342644813     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20170     Document Type: Article

References (50)

1. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
2. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BS. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroentetology 1994;107:1103-1109.
3. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;21:91-100.
4. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
5. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
6. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645-1653.
7. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1998;27:128-133.
8. Ip E, Farrell GC, Robertson GR, Hall P, Kirsch R, Leclercq IA. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. HEPATOLOGY 2003;38:123-132.
9. Lee S, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotrophic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-3022.
10. 2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate. Toxicol Lett 1996;85:143-149.
11. Jedlitschky G, Mayatepek E, Keppler D. Peroxisomal leukotriene degradation: biochemical and clinical implications. Advan Enzyme Regul 1993;33:181-194.
12. Guéraud F, Alary J, Costet P, Debrauwer L, Dolo L, Pineau T, et al. In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARα-deficient mice. J Lipid Res 1999;40:152-159.
13. Delerive P, Bosschert KD, Besnard S, Berghe WV, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 1999;274:32048-32054.
14. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor of α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-32841.
15. Macdonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK, et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominantly in acinar zone 3. Gastroenterol Hepatl 2001;16:599-606.
16. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37:56-62.
17. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-1075.
18. Kumagai T, Kawamoto Y, Nakamura Y, Hatayama I, Satoh K, Osawa T, et al. 4-hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem Biophys Res Commun 2000;273:437-441.
19. Curzio M, Esterbauer H, Dianzani MU. Chemotactic activity of hydroxy-alkenals on rat neutrophils. Int J Tissue React 1985;7:137-142.
20. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myc expression. J Clin Invest 1995;96:2461-2468.
21. Parola M, Pinzani M, Casini A, Leonarduzzi G, Marra F, Caligiuri A, et al. Induction of procollagen type I gene expression and synthesis in human hepatic stellate cells by 4-hydroxy-2,3-nonenal and other 4-hydroxy-2, 3-alkenals is related to their molecular structure. Biochem Biophys Res Commun 1996;222:261-264.
22. George J, Pera N, Phung N, Leclercq IA, Hou JY, Farrell GC. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003;39:756-764.
23. Leclercq IA, Farrell GC, Schreimer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-213.
24. Bancroft J, Stevens A. Theory and Practice of Histological Techniques. 2nd ed. New York: Churchill-Livingstone; 1980:187-188.
25. Willinger CC, Schramek H, Pfaller K, Pfaller W. Tissue distribution of neutrophils in postischemic renal failure. Virchows Archives B Cell Pathology 1992;62:237-243.
26. Stärkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, et al. Oxidative stress, KLF6 and transforming growth factor-β up-regulation differentiate between non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 2003;39:538-546.
27. Iredale JP, Benyon RC, Arthur MJP, Ferris WF, Alcolado R, Winwood PJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. HEPATOLOGY 1996;24:176-184.
28. Watanabe T, Niioka M, Hozawa S, Kameyama K, Hayashi T, Arai M, et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol 2000;33:224-235.
29. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
30. Day CP, James OFW. Hepatic steatosis: innocent bystander of guilty party. HEPATOLOGY 1998;27:1463-1466.
31. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, et al. Fenofibrate prevents and reduced body weight gain and adiposity in diet-induced obese rats. FEBS Lett 2001;491:154-158.
32. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, et al. WY14,643 a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 2002;277:24484-24489.
33. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-3132.
34. Rival Y, Benéteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, et al. PPARα and PPARγ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 2002;435:143-151.
35. Kono H, Uesugi T, Froh M, Rusyn I, Bradford BU, Thurmann RG. ICAM-1 is involved in the mechanism of alcohol-induced liver injury: studies with knockout mice. Am J Physiol Gastrointest Liver Physiol 2001;280:G1289-G1295.
36. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-35722.
37. Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, de Jong J, et al. Peroxisome proliferator-activated, receptor-β signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003;124:184-201.
38. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002;291:55-61.
39. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cells apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-549.
40. Kovalszky I, Nagy P, Szende B, Lapis K, Szalay F, Jeney A, et al. Experimental and human liver fibrogenesis. Scand J Gastroenterol 1998;33(Suppl 228):51-55.
41. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-15225.
42. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999;274:5830-5834.
43. Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, et al. Hepatocyte growth factor counteracts transforming growth factor-β1 through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB J 2002;17:268-270.
44. Williams EJ, Gaça MDA, Brigstock DR, Arthur MJP, Benyon RC. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000;32:754-761.
45. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. HEPATOLOGY 2001;34:738-744.
46. Paradis V, Dargere D, Vidaud M, de Gouville AC, Huet S, Martinez V, et al. Expression of connective tissue growth factor in experimental and human liver fibrosis. HEPATOLOGY 1999;30:968-976.
47. Poulos JE, Weber JD, Bellezzo JM, Di Bisceglie AM, Brirton RS, Bacon BR, et al. Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 1997;273:G804-G811.
48. Palmer CNA, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 1998;53:14-22.
49. Hertz R, Bar-Tana J. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol Lett 1998;102-103:85-90.
50. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, et al. PPAR activators as antiinftammatory mediators in humans T lymphocytes. Circ Res 2002;90:703-710.